This is what caused Rakesh Jhunjhunwala’s untimely death
时间:2024-06-28 23:23:22 阅读(143)
Those who knew Rakesh Jhunjhunwala closely often heard him say that he would ideally want to have his breakfast, do some trading, get back home for dinner, have his drink and then go to sleep and not get up the next day. And as the news of his passing at 7 am on Sunday, August 14th was out, his end was almost as close to the way he had wanted it all concluded. Only, it happened at the Breach Candy hospital.
Also Read: Live updates on Rakesh Jhunjhunwala’s Death – All you need to know
What added to the problems for the other ailments that accompanied him in the form of chronic kidney disease and diabetes. Some who know him, also say that both his kidneys had failed and he was on dialysis. The result of it all has been that Jhunjhunwala often had to visit the Breach Candy Hospital in Mumbai, where he was being treated.
Also Read: Rakesh Jhunjhunwala’s returns formula to be an emperor in stock market
His health problems accumulated so much so that the time spent in the hospital was almost close to four months in the last six months. That he was obese only complicated matters and he would not give up smoking and drinking. The end of an eventful life has however come as a shock to several people and rich tributes continue to flow in.
猜你喜欢
- Windfall tax for domestic crude oil slashed to Rs 4,100 per tonne; no duty on export of diesel, petrol, ATF
- Zomato share price rallies 13%, tops Rs 50 as Q1 net loss halves; should you buy, sell or hold-
- s, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent,” Dr. Aravind Badiger Director, Technical Formulation said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.
- Block-the-Talk- Rohit Arora of Biz2X on the need to balance technological advancements and cybersecurity diligence
- Billionaire Rajiv Jain says will double $2 billion Adani group investment in 5 years; yet Adani scrips fall
- Bihar Education Department deducted salaries of 12,987 absent teachers; suspends 39 and dismisses 13 over violations
- Will Nifty hold 21,400 mark or fall ahead- See GIFT Nifty, FII data, F&O ban, crude, more before market opens
- Rupee likely to depreciate amid strong dollar, elevated crude prices; USDINR pair to trade in this range_1
- Bulls may attempt a comeback to push Nifty above 18100; 5 key things to know before market opening bell